Aggressive immunosuppressant reduction and long-term rejection risk in renal transplant recipients with Pneumocystis jiroveci pneumonia

Experimental and Clinical Transplantation

Volumn 10, Issue 4, 2012, Pages 344-349

  Yang, Chih Yu ^a,b   Shih, Chia Jen ^a,b   Yang, Wu Chang ^a,b   Lin, Chih Ching ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Immunosuppressants; Kidney transplant; Outcomes; Pneumocystis jiroveci pneumonia; Rejection

Indexed keywords

CORTICOSTEROID; COTRIFAMOLE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHENAMINE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ALLOGRAFT; ARTICLE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; GIEMSA STAIN; GOMORI METHENAMINE SILVER STAIN; GRAFT RECIPIENT; GRAFT REJECTION; HOSPITALIZATION; HUMAN; KIDNEY TRANSPLANTATION; LONG TERM CARE; LUNG LAVAGE; MALE; MORTALITY; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; SILVER STAINING; TAIWAN;

ACUTE DISEASE; ADULT; AGED; BRONCHOALVEOLAR LAVAGE FLUID; CHI-SQUARE DISTRIBUTION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TAIWAN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84865069203     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: 10.6002/ect.2012.0015     Document Type: Article

References (19)

1. Elinder CG, Andersson J, Bolinder G, Tydén G. Effectiveness of low-dose cotrimoxazole prophylaxis against Pneumocystis carinii pneumonia after renal and/or pancreas transplantation. Transpl Int. 1992;5(2):81-84.
2. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998;338(24):1741-1751.
3. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Longterm management of the transplant recipient. IV.7.1 Late infections. Pneumocystis carinii pneumonia. Nephrol Dial Transplant. 2002;17(suppl 4):36-39.
4. Branten AJ, Beckers PJ, Tiggeler RG, Hoitsma AJ. Pneumocystis carinii pneumonia in renal transplant recipients. Nephrol Dial Transplant. 1995;10(7):1194-1197.
5. Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC. Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation. 2009;88(1):135-141.
6. Archontoulis NK, Staikou CV. Therapeutic failure in a renal transplant patient with Pneumocystis jiroveci pneumonia: a case report. Exp Clin Transplant. 2009;7(2):129-132.
7. Sileri P, Pursell KJ, Coady NT, et al. A standardized protocol for the treatment of severe pneumonia in kidney transplant recipients. Clin Transplant. 2002;16(6):450-454.
8. Gordon SM, LaRosa SP, Kalmadi S, et al. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis. 1999;28(2):240-246.
9. De Castro N, Xu F, Porcher R, Pavie J, Molina JM, Peraldi MN. Pneumocystis jirovecii pneumonia in renal transplant recipients occurring after discontinuation of prophylaxis: a case-control study. Clin Microbiol Infect. 2010;16(9):1375-1377.
10. Eitner F, Hauser IA, Rettkowski O, et al. Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. Nephrol Dial Transplant. 2011;26(6):2013-2017.
11. Struijk GH, Gijsen AF, Yong SL, et al. Risk of Pneumocystis jiroveci pneumonia in patients long after renal transplantation. Nephrol Dial Transplant. 2011;26(10):3391-3398.
12. Bia M, Adey DB, Bloom RD, Chan L, Kulkarni S, Tomlanovich S. KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Kidney Dis. 2010;56(2):189-218.
13. Knoll GA, Blydt-Hansen TD, Campbell P, et al. Canadian Society of Transplantation and Canadian Society of Nephrology commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Kidney Dis. 2010;56(2):219-246.
14. Hardy AM, Wajszczuk CP, Suffredini AF, Hakala TR, Ho M. Pneumocystis carinii pneumonia in renal-transplant recipients treated with cyclosporine and steroids. J Infect Dis. 1984;149(2):143-147.
15. Lufft V, Kliem V, Behrend M, Pichlmayr R, Koch KM, Brunkhorst R. Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. Transplantation. 1996;62(3):421-423.
16. Dummer JS. Pneumocystis carinii infections in transplant recipients. Semin Respir Infect. 1990;5(1):50-57.
17. Arend SM, Westendorp RG, Kroon FP, et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis. 1996;22(6):920-925.
18. Hennequin C, Page B, Roux P, Legendre C, Kreis H. Outbreak of Pneumocystis carinii pneumonia in a renal transplant unit. Eur J Clin Microbiol Infect Dis. 1995;14(2):122-126.
19. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol. 2007;2(2):374-384.